| pubmed-article:21167778 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21167778 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:21167778 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21167778 | pubmed:dateCreated | 2011-4-12 | lld:pubmed |
| pubmed-article:21167778 | pubmed:abstractText | The renin-angiotensin-system harbours two main receptor subtypes binding angiotensin II which are the AT1-receptor and the AT2-receptor. While the AT1-receptor has been a drug target in cardiovascular disease for many years, the AT2-receptor was only a subject of academic interest. This has changed with the design and synthesis of a first non-peptide, orally active AT2-receptor agonist, compound 21 (C21). First data using C21 revealed tissue protective effects and functional improvement after myocardial infarction and in hypertension-induced end organ damage, notably in a blood-pressure independent way. In all of these models, AT2-receptor mediated anti-inflammation seemed an important underlying mechanism. C21 is awaited to enter a phase I clinical study in 2011. | lld:pubmed |
| pubmed-article:21167778 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21167778 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21167778 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21167778 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21167778 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21167778 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21167778 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21167778 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21167778 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21167778 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:21167778 | pubmed:issn | 1471-4973 | lld:pubmed |
| pubmed-article:21167778 | pubmed:author | pubmed-author:DahlöfBjörnB | lld:pubmed |
| pubmed-article:21167778 | pubmed:author | pubmed-author:UngerThomasT | lld:pubmed |
| pubmed-article:21167778 | pubmed:author | pubmed-author:SteckelingsU... | lld:pubmed |
| pubmed-article:21167778 | pubmed:author | pubmed-author:HallbergAnder... | lld:pubmed |
| pubmed-article:21167778 | pubmed:author | pubmed-author:LarhedMatsM | lld:pubmed |
| pubmed-article:21167778 | pubmed:author | pubmed-author:WiddopRobert... | lld:pubmed |
| pubmed-article:21167778 | pubmed:author | pubmed-author:JonesEmma SES | lld:pubmed |
| pubmed-article:21167778 | pubmed:author | pubmed-author:WallinderChar... | lld:pubmed |
| pubmed-article:21167778 | pubmed:author | pubmed-author:NamsolleckPaw... | lld:pubmed |
| pubmed-article:21167778 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21167778 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21167778 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:21167778 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21167778 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21167778 | pubmed:pagination | 187-92 | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:meshHeading | pubmed-meshheading:21167778... | lld:pubmed |
| pubmed-article:21167778 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21167778 | pubmed:articleTitle | Non-peptide AT2-receptor agonists. | lld:pubmed |
| pubmed-article:21167778 | pubmed:affiliation | Center for Cardiovascular Research, Charité-Universitätsmedizin Berlin, Hessische Str. 3-4, 10115 Berlin, Germany. ulrike.steckelings@charite.de | lld:pubmed |
| pubmed-article:21167778 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21167778 | pubmed:publicationType | Review | lld:pubmed |
